Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: FJB who wrote (3256)	4/29/2011 3:36:33 PM
From: Savant	Respond to of 3576

A + B, I believe. Some vol today.

To: FJB who wrote (3256)	5/2/2011 11:08:15 AM
From: Savant	Read Replies (1) \| Respond to of 3576

Shares of several stem-cell-research groups were on a roll early Monday in the wake of a U.S. appeals court decision Friday that will allow researchers who experiment with human embryonic stem cells to apply for federal funding through the National Institutes of Health. StemCells Inc. (STEM) was the lead advancer, with shares rallying 9.3% to 92 cents, followed by Advanced Cell Technology Inc. (ACTC), up 9%. Also gaining were Pluristem Therapeutics Inc. (PSTI), up 6%; Aastrom Biosciences Inc. (ASTM), up 5.6%; and Geron Corp. (GERN), up 2.5%.